Published in Diabetes Care on July 20, 2011
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia (2011) 3.52
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care (2012) 1.76
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) (2014) 1.38
Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf (2013) 1.05
Latest insights into the risk of cancer in diabetes. J Diabetes Investig (2013) 1.01
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care (2013) 0.97
Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One (2014) 0.91
Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. Medicine (Baltimore) (2016) 0.90
Insulin therapy and cancer. Diabetes Care (2013) 0.87
The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem (2013) 0.86
Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. Cancer Med (2014) 0.85
Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care (2013) 0.85
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res (2015) 0.85
Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One (2012) 0.85
Association between Metformin Therapy and Breast Cancer Incidence and Mortality: Evidence from a Meta-Analysis. J Breast Cancer (2015) 0.85
Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS One (2014) 0.84
The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med (2014) 0.84
Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab (2013) 0.83
Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol (2012) 0.82
Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PLoS One (2013) 0.81
Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer (2014) 0.80
Diabetes, glucose control, glucose lowering medications, and cancer risk: a 10-year population-based historical cohort. BMC Cancer (2012) 0.80
Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies. PLoS One (2013) 0.78
Comment on: Morden et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011;34:1965-1971. Diabetes Care (2012) 0.77
Metformin therapy and prostate cancer risk: a meta-analysis of observational studies. Int J Clin Exp Med (2015) 0.77
Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. PLoS One (2014) 0.77
Smoking habits and benign prostatic hyperplasia: A systematic review and meta-analysis of observational studies. Medicine (Baltimore) (2016) 0.76
Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes Control (2016) 0.75
Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes Control (2015) 0.75
Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study. Diabetes Ther (2016) 0.75
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2. Endocr Relat Cancer (2016) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Insulin analogues. N Engl J Med (2005) 12.24
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia (2009) 7.06
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia (2009) 3.89
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia (2009) 3.82
Does diabetes therapy influence the risk of cancer? Diabetologia (2009) 3.66
The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology (2007) 3.60
Insulin glargine and malignancy: an unwarranted alarm. Lancet (2009) 3.19
Obesity and cancer. Oncologist (2010) 3.01
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003) 2.90
Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem (2008) 2.40
Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia (2009) 2.34
Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr (2007) 2.05
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia (2009) 2.04
Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control (2007) 1.66
Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.60
Insulin glargine and cancer. Lancet (2009) 0.81
Regional variations in diagnostic practices. N Engl J Med (2010) 7.44
Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology (2012) 4.13
Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med (2009) 3.85
Sources of regional variation in Medicare Part D drug spending. N Engl J Med (2012) 3.17
Large variations in Medicare payments for surgery highlight savings potential from bundled payment programs. Health Aff (Millwood) (2011) 3.05
MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 2.95
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol (2009) 2.66
Racial and ethnic differences in preferences for end-of-life treatment. J Gen Intern Med (2009) 2.58
Fluorescence spectroscopic profiling of compound libraries. J Med Chem (2008) 2.53
Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res (2004) 2.48
Rice consumption and urinary arsenic concentrations in U.S. children. Environ Health Perspect (2012) 2.44
Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res (2009) 2.43
Ventilation of patients with acute lung injury and acute respiratory distress syndrome: has new evidence changed clinical practice? Crit Care Med (2004) 2.33
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
Churning: the association between health care transitions and feeding tube insertion for nursing home residents with advanced cognitive impairment. J Palliat Med (2009) 2.18
The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A (2007) 2.18
The seasonality of postoperative infection in spine surgery. J Neurosurg Spine (2012) 2.14
Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun (2009) 2.04
Effect of prior cardiac operations on survival after coronary artery bypass grafting. Ann Thorac Surg (2011) 2.02
Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J (2006) 1.98
Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J (2006) 1.94
Molecular origin of high field-effect mobility in an indacenodithiophene-benzothiadiazole copolymer. Nat Commun (2013) 1.94
Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med (2012) 1.92
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem (2008) 1.87
Medicare upcoding and hospital ownership. J Health Econ (2004) 1.84
Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther (2006) 1.71
Retracted Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol (2012) 1.67
Perioperative increases in serum creatinine are predictive of increased 90-day mortality after coronary artery bypass graft surgery. Circulation (2006) 1.53
Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res (2012) 1.51
Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol (2005) 1.51
Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res (2010) 1.44
Direct endoscopic necrosectomy for the treatment of walled-off pancreatic necrosis: results from a multicenter U.S. series. Gastrointest Endosc (2011) 1.44
Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol (2004) 1.43
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest (2008) 1.43
Mortality in Medicare patients undergoing elective percutaneous coronary intervention with or without antecedent stress testing. Circ Cardiovasc Qual Outcomes (2013) 1.41
Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol (2010) 1.39
Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc (2013) 1.38
Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics (2006) 1.34
State spending on dual eligibles under age 65 shows variations, evidence of cost shifting from Medicaid to Medicare. Health Aff (Millwood) (2012) 1.31
Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol Ther (2007) 1.28
Magnetic enhancement of cell retention, engraftment, and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion. Cell Transplant (2012) 1.28
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res (2007) 1.27
Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res (2007) 1.26
Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol (2003) 1.22
Indacenodithiophene semiconducting polymers for high-performance, air-stable transistors. J Am Chem Soc (2010) 1.20
Factors affecting the probability of first year medical student dropout in the UK: a logistic analysis for the intake cohorts of 1980-92. Med Educ (2004) 1.19
Adhesion molecules in human pancreatic cancer. J Surg Oncol (2002) 1.19
Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin Cancer Res (2003) 1.19
14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness. Clin Cancer Res (2008) 1.17
Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas (2013) 1.15
Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J Proteome Res (2006) 1.14
Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther (2011) 1.13
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.13
FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer (2006) 1.12
Independent and parallel lateral transfer of DNA transposons in tetrapod genomes. Gene (2009) 1.12
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology (2003) 1.11
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther (2002) 1.11
Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. PLoS One (2011) 1.11
Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am J Pathol (2007) 1.10
Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther (2012) 1.10
Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum Pathol (2008) 1.10
Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. J Clin Invest (2013) 1.10
Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther (2010) 1.09
Induction and expression of betaig-h3 in pancreatic cancer cells. Biochim Biophys Acta (2002) 1.08
Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog (2002) 1.07
Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PLoS One (2011) 1.07
Public directory data sources do not accurately characterize the food environment in two predominantly rural states. J Am Diet Assoc (2011) 1.06
Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis (2004) 1.06
Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology (2011) 1.05
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene (2004) 1.05
Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem (2008) 1.04
Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Cancer Res (2004) 1.03
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells. Cancer Biol Ther (2011) 1.03
High mobility field-effect transistors with versatile processing from a small-molecule organic semiconductor. Adv Mater (2013) 1.02
Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res (2004) 1.02
Defined localization of nestin-expressing cells in L-arginine-induced acute pancreatitis. Pancreas (2006) 1.01
Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg (2008) 1.01
Coarse-grained force field for the nucleosome from self-consistent multiscaling. J Comput Chem (2008) 1.01
Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison. Ann Intern Med (2013) 1.01
Transplantation of platelet gel spiked with cardiosphere-derived cells boosts structural and functional benefits relative to gel transplantation alone in rats with myocardial infarction. Biomaterials (2012) 1.00
Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis (2008) 0.99
Signaling pathways in pancreatic cancer. Crit Rev Eukaryot Gene Expr (2011) 0.99
A longitudinal analysis of rural and urban veterans' health-related quality of life. J Rural Health (2010) 0.98
Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol (2004) 0.98
Microarray analysis of cytoplasmic versus whole cell RNA reveals a considerable number of missed and false positive mRNAs. RNA (2009) 0.98
Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett (2008) 0.96
Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest (2003) 0.96
Measuring racial disparities in the quality of ambulatory diabetes care. Med Care (2010) 0.96
DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS One (2011) 0.96
Involvement of microRNAs in lung cancer biology and therapy. Transl Res (2011) 0.96
Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol (2012) 0.95
Intramyocardial injection of platelet gel promotes endogenous repair and augments cardiac function in rats with myocardial infarction. J Am Coll Cardiol (2012) 0.95
Inherent and benzo[a]pyrene-induced differential aryl hydrocarbon receptor signaling greatly affects life span, atherosclerosis, cardiac gene expression, and body and heart growth in mice. Toxicol Sci (2012) 0.94
Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant (2012) 0.93
Connective tissue growth factor is involved in pancreatic repair and tissue remodeling in human and rat acute necrotizing pancreatitis. Ann Surg (2002) 0.93
Impact of workplace sociocultural attributes on participation in health assessments. J Occup Environ Med (2009) 0.93
A blinded, randomized controlled evaluation of an impedance threshold device during cardiopulmonary resuscitation in swine. Resuscitation (2008) 0.93